-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind reports continued CMND-100 Phase I/IIa cohort 3 treatment with no serious adverse events at U.S. sites

Reuters·03/19/2026 14:58:18

Please log in to view news